Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Current Deferred Revenue: 2010-2024

Historic Current Deferred Revenue for Ligand Pharmaceuticals (LGND) over the last 12 years, with Dec 2024 value amounting to $1.3 million.

  • Ligand Pharmaceuticals' Current Deferred Revenue fell 90.72% to $111,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $111,000, marking a year-over-year decrease of 90.72%. This contributed to the annual value of $1.3 million for FY2024, which is 4.58% up from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Current Deferred Revenue stood at $1.3 million for FY2024, which was up 4.58% from $1.2 million recorded in FY2023.
  • In the past 5 years, Ligand Pharmaceuticals' Current Deferred Revenue registered a high of $29.4 million during FY2020, and its lowest value of $355,000 during FY2022.
  • Over the past 3 years, Ligand Pharmaceuticals' median Current Deferred Revenue value was $1.2 million (recorded in 2023), while the average stood at $951,667.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first skyrocketed by 1,276.11% in 2020, then plummeted by 97.78% in 2021.
  • Ligand Pharmaceuticals' Current Deferred Revenue (Yearly) stood at $29.4 million in 2020, then tumbled by 97.78% to $654,000 in 2021, then plummeted by 45.72% to $355,000 in 2022, then surged by 244.23% to $1.2 million in 2023, then climbed by 4.58% to $1.3 million in 2024.